Rchr
J-GLOBAL ID：200901001388786641   Update date: Sep. 19, 2024

Nishibori Masahiro

西堀 正洋 | Nishibori Masahiro
Affiliation and department：
Okayama University

About Okayama University


Job title： Specifically-appointed Professor
Homepage URL  (2)： https://www.okayama-u.ac.jp/user/translre/ ,  https://www.okayama-u.ac.jp/user/translre/en/
Research field  (2)： Medical biochemistry ,  Pharmacology
Research keywords  (4)： 医化学一般 ,  薬理学一般 ,  Biochemistry ,  Pharmacology
Research theme for competitive and other funds  (42)：
  • 2023 - 2026 S100A8/A9-向転移とHRG-抗転移の細胞間・分子間クロストークの解明
  • 2021 - 2024 Verification of preventative effects of monoclonal HMGB1 antibody for spinal cord injury after aortic operation
  • 2021 - 2024 HMGB1-HRGバランスに着目した川崎病新規治療薬の開発
  • 2020 - 2023 組織障害性HMGB1に着眼した肺虚血再灌流障害に対する新規戦略の確立
  • 2020 - 2023 新規S100A8/A9阻害分子の発見に基づいたがん脳指向転移の機構解明とその制御
Show all
Papers (301)：
  • Shangze Gao, Dengli Wang, Keyue Liu, Yasuko Tomono, Li Fu, Yuan Gao, Yohei Takahashi, Mariko Yata, Masahiro Nishibori. Anti-HMGB1 mAb Therapy Reduces Epidural Hematoma Injury. International journal of molecular sciences. 2024. 25. 11
  • Masahiro Nishibori, Hidenori Wake, Masakiyo Sakaguchi. The plasma protein HRG is an important factor for preventing sepsis and maintaining homeostatic response. Folia Pharmacologica Japonica. 2024. 159. 2. 107-111
  • Simeng Ma, Yoki Nakamura, Takahiro Kochi, Suzuna Uemoto, Kazue Hisaoka-Nakashima, Dengli Wang, Keyue Liu, Hidenori Wake, Masahiro Nishibori, Norimitsu Morioka. Perineural Treatment with High Mobility Group Box-1 Monoclonal Antibody Prevents Initiation of Pain-Like Behaviors in Female Mice with Trigeminal Neuropathy. Biological and Pharmaceutical Bulletin. 2024. 47. 1. 221-226
  • Masahiro Watanabe, Takao Toyomura, Hidenori Wake, Takashi Nishinaka, Omer Faruk Hatipoglu, Hideo Takahashi, Masahiro Nishibori, Shuji Mori. Cationic ribosomal proteins can inhibit pro-inflammatory action stimulated by LPS+HMGB1 and are hindered by advanced glycation end products. Biotechnology and applied biochemistry. 2023
  • Takashi Nishinaka, Omer Faruk Hatipoglu, Hidenori Wake, Masahiro Watanabe, Takao Toyomura, Shuji Mori, Masahiro Nishibori, Hideo Takahashi. Different modulation of STING/TBK1/IRF3 signaling by advanced glycation end products. Archives of biochemistry and biophysics. 2023. 750. 109808-109808
ｍore...
MISC (195)：
  • 友信奈保子, 木下理恵, 合原勇馬, KOMALASARI Ni Luh Gede Yoni, JIANG Fan, 村田等, 山本健一, 山内明, 近藤英作, 豊岡伸一, et al. HRG suppresses the S100A8/A9-mediated metastasis of melanoma cells. 組織培養研究(Web). 2023. 41. 2
  • 逢坂 大樹, 西堀 正洋. 溶血に伴うDAMPs処理をターゲットにした敗血症(COVID-19含む)に対する治療法の開発-A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs-特集 Damage-associated molecular patterns (DAMPs)の制御機構と創薬シーズへの応用. 日本薬理学雑誌 = Folia pharmacologica Japonica : くすりとからだ : ファーマコロジカ. 2022. 157. 6. 422-425
  • Daiki Ousaka, Masahiro Nishibori. Is hemolysis a novel therapeutic target in COVID-19?. FRONTIERS IN IMMUNOLOGY. 2022. 13
  • 圓尾賢悟, 池田裕哉, 坪田真帆, 王登莉, 西堀正洋, 南達郎, 伊藤彰敏, 川畑篤史. 活性化プロテインCは神経障害性疼痛を抑制する:Proteinase-activated receptor-1(PAR1)の関与について. 生体機能と創薬シンポジウム要旨集. 2022. 2022
  • 圓尾賢悟, 坪田真帆, 田島和樹, 関口富美子, 西堀正洋, 南達郎, 伊藤彰敏, 川畑篤史. Thrombomodulin alfaのoxaliplatin誘発性末梢神経障害抑制作用発現におけるHMGB1不活性化とprotein C及びTAFI活性化の相対的重要性と下流シグナル分子の解析. 日本薬理学雑誌. 2022. 157. Supplement
ｍore...
Patents (18)：
  • 好中球活性化に起因する疾患の治療薬及び検査方法(JP:医療技術)
  • 外傷性神経障害治療剤(JP)
  • ヒト化抗HMGB1抗体もしくはその抗原結合性断片(JP)
  • HUMANIZED ANTI-HMGBl ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
  • THERAPEUTIC AGENT, METHOD OF TREATMENT AND METHOD FOR PREDICTING THE SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS), DISEASES CAUSED OR ACCOMPANIED BY NEUTROPHIL ACTIVATION
ｍore...
Lectures and oral presentations  (249)：
  • 虚血性脳障害の鍵分子HMGB1と標的抗体治療
    (第53回広島神経医科学研究会 2018)
  • Histidine-rich glycoprotein (HRG)の好中球制御による敗血症治療薬の可能性
    (第132回日本薬理学会近畿部会 2017)
  • Involvement of HMGB1 in postoperative pain.
    (Neuroscience 2017 2017)
  • Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice.
    (8th International DAMPs and Alarmins Symposium 2017)
  • Anti-HMGB1 monoclonal antibody therapy for broad range of CNS injuries: development of humanized antibody.
    (8th International DAMPs and Alarmins Symposium 2017)
ｍore...
Works (1)：
  • 平成21年度 全国発明表彰 21世紀発明奨励賞
    2009 -
Education (2)：
  • - 1980 Okayama University Medical School Faculty of Medicine
  • - 1980 Okayama University Faculty of Medicine
Professional career (1)：
  • Doctor of philosophy (Okayama University)
Work history (10)：
  • 2021/04 - 現在 Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences Department of Translational Research & Drug Development Specifically-appointed Professor
  • 2001/04 - 2021/03 - 岡山大学医歯薬学総合研究科 教授
  • 1995 - 2001 Okayama University Medical School
  • 2001 - - Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University
  • 1988 - 1995 Okayama University Medical School
Show all
Committee career (1)：
  • 1988 - 現在 日本薬理学会 学術評議員
Awards (9)：
  • 2021/03 - 公益社団法人日本薬理学会 第14回江橋節郎賞
  • 2015 - セコム科学技術振興財団研究奨励賞
  • 2014 - ライフサイエンス振興財団創立30周年記念特別研究奨励賞
  • 2012 - 山陽新聞賞奨励賞(学術功労)
  • 2012 - バイオビジネスアワードJapan2012彩都賞
Show all
Association Membership(s) (5)：
国際薬理学会議 ,  日本ヒスタミン学会 ,  米国神経科学会(Society for Neuroscience) ,  日本神経科学会 ,  日本薬理学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM